ReviewJournal of nutrition and metabolism2026
Natural Fish Oil Versus Purified Fish Oil: Composition, Efficacy, and Applications.
Review in Journal of nutrition and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review proposes a purity-bioavailability-indication framework to systematically differentiate natural fish oil (NFO) and purified fish oil (PFO) and guide clinical decision-making. We categorize fish oil formulations along a therapeutic gradient from nutritional maintenance to targeted intervention, with molecular structure stratification based on bioavailability and safety profiles. NFO retains natural triglyceride structures with superior absorption kinetics but lower ω-3 polyunsaturated fatty acid (PUFA) purity, positioning it for maintenance nutritional supplementation. PFO, through advanced purification, achieves higher purity in ethyl esters (EEs), free fatty acids (FFAs), and re-esterified triglycerides (rTG) forms. The rTG structure uniquely combines high purity with enhanced bioavailability, bridging the gap between NFO and conventional PFO. Within the PFO category, our framework distinguishes eicosapentaenoic acid ethyl ester (EPA-EE) as the evidence-based choice for atherosclerotic cardiovascular disease (ASCVD) risk reduction, combinations of EPA and docosahexaenoic acid (EPA/DHA) as neutral for cardiovascular outcomes, and rTG as the bioavailable alternative for enteral therapeutic applications. For parenteral nutrition, PFO-based lipid emulsions provide formulation and operational advantages. In summary, this framework identifies a fundamental trade-off between natural matrix preservation (NFO) and purity/bioavailability optimization (PFO). PFO, particularly high-purity EPA-EE formulations, demonstrates established efficacy in cardiovascular risk reduction, while rTG offers superior bioavailability with comparable clinical promise; both PFO formulations show advantages in parenteral nutrition. High-dose ω-3 formulations, regardless of EPA monotherapy or EPA/DHA combination, carry a dose-dependent atrial fibrillation risk that warrants age-stratified assessment. NFO remains preferable for general nutritional supplementation given its favorable tolerability and preservation of natural antioxidants. Selection between NFO and PFO should be guided by clinical indication, required dosage, and arrhythmia risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.